QCOR News 91.88 06/24/2014 05:23:21 Questcor Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 91.88 $QCOR

Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
PR Newswire - Mon Jun 23, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin peptide. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for multiple indications, including certain autoimmune and inflammatory conditions as well as for diagnostic use, but have never been developed or approved for patients in the U.S. Questcor is presently engaged in pre-clinical development for Synacthen in the U.S.

Shares of QCOR Up 38.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 37.98% as of today's recent price of $93.01.

Look for Shares of Questcor Pharmaceuticals to Potentially Pullback after Yesterday's 2.84% Rise
Comtex SmarTrend(R) - Tue Jun 17, 4:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.15 to a high of $91.68. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $90.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 32.3% (QCOR)
Comtex SmarTrend(R) - Fri Jun 13, 9:09AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 32.27% as of today's recent price of $89.16.

FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

Shares of QCOR Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 29.45% as of today's recent price of $87.26.

Lannett Tops Trio Of Medical Small Cap Leaders
at Investor's Business Daily - Thu Jun 05, 7:02AM CDT
Small, fast-growing companies in hot industries, such as generics drugmaker Lannett, are good prospects for a stock watch list. Today's Screen Of The Day is Small Cap Leaders, highly rated companies with a market capitalization of $300 million to $2...

Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte
PR Newswire - Thu Jun 05, 7:00AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average advanced 0.09%, to finish the day at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index also advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Nektar Therapeutics (NASDAQ: NKTR) and Endocyte Inc. (NASDAQ: ECYT). Free technical research on AKRX, QCOR, NKTR and ECYT can be downloaded upon signing up at:

Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
PR Newswire - Tue Jun 03, 9:28AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities.

FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.

SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.43% Gain
Comtex SmarTrend(R) - Mon Jun 02, 4:25PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $89.51 to a high of $92.38. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $90.50 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...

Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Wed May 28, 5:39PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.75 to a high of $90.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.75 on volume of 702,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Questcor Receives "Recognition of Appreciation" Award from MS Views & News
PR Newswire - Wed May 28, 2:28PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization.

Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...

Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.

Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 53

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 161

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leech Tishman Expands Healthcare Practice with Nelson Hardiman

Updated Category News Views 79

Leech Tishman Expands Its Healthcare Practice with Major Addition Leech Tishman is making a significant move in its growth strategy by merging with the respected healthcare firm, Nelson Hardiman. This collaboration is set to enhance Leech Tishman’s footprint in the healthcare sector, especially in the Southern California region, as they prepare to operate under the name...

Continue Reading
Schouw & Co. Announces Success in Share Buy-Back Program

Updated Category News Views 105

Schouw & Co. Share Buy-Back Program Overview Schouw & Co., a notable player in the business landscape, has embarked on an impactful share buy-back program that began recently. This strategic move allows the company to purchase shares worth up to DKK 50 million over a designated time frame, from January 2 to March 31. Such initiatives reflect the company's commitment to...

Continue Reading
Earnings Season Set to Shape Market Dynamics Amid Tariffs

Updated Category News Views 150

Understanding Market Sentiment During Earnings Season The upcoming earnings season presents an opportunity for Wall Street to shift its attention from external geopolitical factors to the internal dynamics of corporate performance. As companies prepare to unveil their second-quarter earnings reports, a closer look at how tariffs could influence consumer spending and,...

Continue Reading
Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth

Updated Category News Views 316

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) has announced the addition of Josh Ruben to its Board of Directors. This news comes from the company's efforts to further establish itself within the biomedical device sector aimed at improving the quality of life for companion animals. Transformational Leadership...

Continue Reading
Innovative Portable Solar and Wind Generator Concept Unveiled

Updated Category News Views 120

Your Sustainable Charging Solution We live in a time where sustainable energy solutions are becoming more paramount, and the invention of a portable solar and wind-powered generator meets that demand head-on. The concept builds on the idea that everyone deserves access to clean energy alternatives, especially for charging electronic devices. The Vision Behind the...

Continue Reading